Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13112663
Abstract: Simple Summary Glioblastoma (GB) is an aggressive brain tumour with poor survival. Tumour microenvironment is a key element in GB evolution and response to therapy. We assessed presence and phenotypes of microglia/macrophages in preclinical GL261-GB… read more here.
Keywords: preclinical gl261; system; mrsi; immune system ... See more keywords
Course of Aggressive Somatotroph, Corticotroph and Mammotroph Tumors under Temozolomide; Report of Three Cases and Review of the Literature.
Sign Up to like & getrecommendations! Published in 2017 at "Turkish neurosurgery"
DOI: 10.5137/1019-5149.jtn.20216-17.1
Abstract: Treatment of aggressive pituitary tumors may be challenging. Temozolomide (TMZ) is a promising agent when conventional treatment methods fail. We present three patients with aggressive pituitary tumors with atypical morphology, who were resistant to conventional… read more here.
Keywords: corticotroph mammotroph; treatment; somatotroph corticotroph; tmz treatment ... See more keywords